PMCB (PharmaCyte Biotech) Other Stockholders Equity: $0.42 Mil (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.77
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Other Stockholders Equity?

PharmaCyte Biotech PMCB +0.51% 32 Other Stockholders Equity is $0.42 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Other Stockholders Equity for the quarter that ended in Jan. 2026 was $0.42 Mil.

PharmaCyte Biotech's quarterly Other Stockholders Equity increased from Jul. 2025 ($0.00 Mil) to Oct. 2025 ($0.42 Mil) but then declined from Oct. 2025 ($0.42 Mil) to Jan. 2026 ($0.42 Mil).

PharmaCyte Biotech's annual Other Stockholders Equity increased from Apr. 2023 ($0.00 Mil) to Apr. 2024 ($0.00 Mil) but then declined from Apr. 2024 ($0.00 Mil) to Apr. 2025 ($-0.00 Mil).

PharmaCyte Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Other Stockholders Equity Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.42 0.42
PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.42 Mil mean?
PharmaCyte Biotech (PMCB) has a Other Stockholders Equity of $0.42 Mil as of Jan. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Other Stockholders Equity too high?
PharmaCyte Biotech's current Other Stockholders Equity is $0.42 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Other Stockholders Equity compare to ERNA and SYBX?
PharmaCyte Biotech's Other Stockholders Equity of $0.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Other Stockholders Equity is $0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Other Stockholders Equity of $0.42 Mil. The current Other Stockholders Equity is $0.42 Mil. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Other Stockholders Equity is $0.42 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price